Kun Zhang

ORCID: 0000-0003-2401-1858
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Epigenetics and DNA Methylation
  • Cancer Cells and Metastasis
  • Cancer, Hypoxia, and Metabolism
  • Lung Cancer Research Studies
  • Retinoids in leukemia and cellular processes
  • Veterinary medicine and infectious diseases
  • Cell death mechanisms and regulation
  • Endoplasmic Reticulum Stress and Disease
  • Bioactive Compounds and Antitumor Agents
  • Ubiquitin and proteasome pathways
  • Acute Myeloid Leukemia Research
  • Protein Degradation and Inhibitors
  • Toxin Mechanisms and Immunotoxins
  • Peptidase Inhibition and Analysis
  • Histone Deacetylase Inhibitors Research

Nankai University
2021-2025

State Key Laboratory of Medicinal Chemical Biology
2024-2025

State Key Laboratory of Chemical Engineering
2025

Small-cell lung cancer (SCLC) represents a significant public health challenge due to its increasing incidence and high mortality. Most SCLC patients are diagnosed at advanced stages, there limited effective targeted therapies available. In this study, potent selective CDK9 degrader, C3, was developed through PROTAC modification of the inhibitor, AT-7519. C3 effectively induced apoptosis in various cell lines low nanomolar concentrations demonstrated favorable vivo tolerance adequate oral...

10.1021/acs.jmedchem.4c01621 article EN Journal of Medicinal Chemistry 2025-02-02

Cancer stem cells (CSCs) play a pivotal role in tumor initiation, proliferation, metastasis, drug resistance, and recurrence. Consequently, targeting CSCs has emerged as promising avenue for cancer therapy. Recently, 3-phosphoglycerate dehydrogenase (PHGDH) been identified being intricately associated with the regulation of numerous cells. Yet, reports detailing functional regulators PHGDH that can mitigate stemness across types are limited. In this study, novel "molecular glue" LXH-3-71 was...

10.1016/j.apsb.2024.06.001 article EN cc-by-nc-nd Acta Pharmaceutica Sinica B 2024-06-07

Necroptosis has been recently confirmed as a non-apoptotic form of programmed cell death. Discovery novel chemical entities, capable inducing necroptosis cancer cells, is likely to act an alternative strategy for dealing with drug resistance clinically. In this study, the identification Pleuromutilin derivative (compound 38) presented, significantly increasing cellular level ROS and melanoma death via necroptosis. Furthermore, compound 38 noticeably ablated various stem cells inhibited...

10.1021/acs.jmedchem.1c01123 article EN Journal of Medicinal Chemistry 2021-10-27
Coming Soon ...